MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MediciNova Inc (MNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012278
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs such as MN-001, for the treatment of nonalcoholic steatohepatitis; MN-166, for neurological disorders; and MN-221, for respiratory diseases. The company’s non-core programs include MN-001 being developed for two indications, namely, bronchial asthma and interstitial cystitis; MN-029 for the treatment of solid tumors; and MN-221 for the treatment of preterm labor. It has partnerships with various companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd and Meiji Seika Kaisha Ltd., to develop and commercialize its products. MediciNova is headquartered in California, the US.

MediciNova Inc (MNOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MediciNova Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
MediciNova Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediciNova Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 10
MediciNova Forms Joint Venture With Zhejiang Medicine 11
Licensing Agreements 12
MediciNova Enters Into Licensing Agreement With University of Colorado Boulder For Ibudilast 12
Equity Offering 13
MediciNova Plans to Raise up to USD200 Million in Public Offering of Securities 13
MediciNova to Raise up to USD30 Million in Public Offering of Shares 14
MediciNova Raises USD17.5 Million in Public Offering of Shares 15
MediciNova Completes First Tranche Of Public Offering Of Common Stock For US$2.8 Million 16
MediciNova Completes First Tranche Of Private Placement Of Common Stock For US$1 Million 17
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For US$7.5 Million 18
MediciNova Completes An Underwritten Public Offering Of Units For US$8.4 Million 20
MediciNova Inc – Key Competitors 22
MediciNova Inc – Key Employees 23
MediciNova Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Nov 09, 2017: MediciNova Appoints Hideki Nagao to its Board of Directors 25
Dec 14, 2016: MediciNova Added to NASDAQ Biotechnology Index 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
MediciNova Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MediciNova Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MediciNova Inc, Deals By Therapy Area, 2011 to YTD 2017 8
MediciNova Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 10
MediciNova Forms Joint Venture With Zhejiang Medicine 11
MediciNova Enters Into Licensing Agreement With University of Colorado Boulder For Ibudilast 12
MediciNova Plans to Raise up to USD200 Million in Public Offering of Securities 13
MediciNova to Raise up to USD30 Million in Public Offering of Shares 14
MediciNova Raises USD17.5 Million in Public Offering of Shares 15
MediciNova Completes First Tranche Of Public Offering Of Common Stock For US$2.8 Million 16
MediciNova Completes First Tranche Of Private Placement Of Common Stock For US$1 Million 17
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For US$7.5 Million 18
MediciNova Completes An Underwritten Public Offering Of Units For US$8.4 Million 20
MediciNova Inc, Key Competitors 22
MediciNova Inc, Key Employees 23
MediciNova Inc, Subsidiaries 24

★海外企業調査レポート[MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Far Eastone Telecommunications Co Ltd (4904):企業の財務・戦略的SWOT分析
    Far Eastone Telecommunications Co Ltd (4904) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Chromalloy Gas Turbine LLC:企業の戦略・SWOT・財務情報
    Chromalloy Gas Turbine LLC - Strategy, SWOT and Corporate Finance Report Summary Chromalloy Gas Turbine LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rajesh Exports Limited
    Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report Summary Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hitachi Metals, Ltd.:企業の戦略・SWOT・財務分析
    Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ZincX Resources Corp:企業の戦略・SWOT・財務分析
    ZincX Resources Corp - Strategy, SWOT and Corporate Finance Report Summary ZincX Resources Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fomento de Construcciones y Contratas SA (FCC)-エネルギー分野:企業M&A・提携分析
    Summary Fomento de Construcciones y Contratas SA (FCC) is a citizen services company. It manages and treats domestic and industrial waste; provides integrated water management services; and designs, develops and maintains infrastructure. The company provides engineering and construction services for …
  • Tec-Masters Inc:企業の戦略・SWOT・財務情報
    Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report Summary Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Amphenol Corporation:企業の戦略・SWOT・財務情報
    Amphenol Corporation - Strategy, SWOT and Corporate Finance Report Summary Amphenol Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Trovagene Inc (TROV)-製薬・医療分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Memorial Resource Development Corp-石油・ガス分野:企業M&A・提携分析
    Summary Memorial Resource Development Corp (Memorial Resource) is an independent natural gas and oil company. It focuses on the exploitation, development, and acquisition of natural gas, natural gas liquids (NGL) and oil properties, primarily in the Cotton Valley formation in North Louisiana. Its pr …
  • Celldex Therapeutics, Inc.:企業の戦略・SWOT・財務分析
    Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Celldex Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Micromem Technologies Inc (MRM):企業の財務・戦略的SWOT分析
    Summary Micromem Technologies Inc (Micromem) is a technology company that develops and markets magnetic sensor products. The company designs and develops sensors specific to industrial requirements. It offers solutions such as nanoparticle detection solutions, structural integrity sensors, oil well …
  • Xencor Inc (XNCR):製薬・医療:M&Aディール及び事業提携情報
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • NW Natural Gas Co:企業の戦略的SWOT分析
    NW Natural Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Antitope Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibo …
  • Electronic Arts Inc.:企業の戦略・SWOT・財務情報
    Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report Summary Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Virtusa Corp (VRTU):企業の財務・戦略的SWOT分析
    Virtusa Corp (VRTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Salzgitter Klockner-Werke GmbH:企業の戦略・SWOT・財務情報
    Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report Summary Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Amtek Auto Limited:企業のM&A・事業提携・投資動向
    Amtek Auto Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Amtek Auto Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Moberg Pharma AB (MOB):企業の財務・戦略的SWOT分析
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆